Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer

• Publication date

  2005-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.21370PMID 16138364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2004

  2004cited by this paper
• Overview of bladder cancer trials in the European Organization for Research and Treatment

  2003cited by this paper
• Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study.

  2003cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Overview of bladder cancer trials in the European Organization for Research and Treatment

  2003cited by this paper
• Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

  2001cited by this paper
• The role of adjuvant chemotherapy for locally advanced bladder cancer

  2001cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

  2000cited by this paper
• Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.

  2000cited by this paper
• Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.

  2000cited by this paper
• Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract

  2000cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial

  1998cited by this paper
• Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.

  1998cited by this paper
• Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.

  1997cited by this paper
• An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

  1994cited by this paper
• Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

  1994cited by this paper
• Carboplatin-based chemotherapy for bladder cancer.

  1993cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

  1990cited by this paper
• Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.

  1990cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Cancer statistics

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• Treatment

  1973cited by this paper

• Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma

  2025cites this paper
• Extended field chemoradiation in M1a bladder carcinoma: A case report.

  2025cites this paper
• Clinical Outcomes of Neoadjuvant Paclitaxel/Cisplatin/Gemcitabine Compared with Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer.

  2025cites this paper
• Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma

  2021cites this paper
• Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.

  2021cites this paper
• The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

  2019cites this paper
• SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

  2018cites this paper
• The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.

  2017cites this paper
• Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.

  2016cites this paper
• Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis

  2016cites this paper
• Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.

  2016cites this paper
• Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.

  2016cites this paper
• Second-line therapies in metastatic urothelial carcinoma.

  2015cites this paper
• Options in metastatic urothelial cancer after first-line therapy

  2015cites this paper
• Management of Metastatic Bladder Tumours

  2015cites this paper
• Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.

  2015cites this paper
• Salvage Treatment with Low-Dose Weekly Paclitaxel in Elderly or Poor Performance Status Patients with Metastatic Urothelial Carcinoma

  2014cites this paper
• Th e First Slovak Experience with Second-line Vinfl unine in Advanced Urothelial Carcinomas Prvá slovenská skúsenosť s použitím vinfl unínu v druhej línii liečby pokročilých urotelových karcinómov

  2014cites this paper
• Methotrexate‐paclitaxel‐epirubicin‐carboplatin as second‐line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin‐gemcitabine: A phase II study

  2013cites this paper
• Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma

  2013cites this paper
• Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

  2013cites this paper
• Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin – preliminary results

  2012cites this paper
• First- and second-line therapy for metastatic urothelial carcinoma of the bladder.

  2011cites this paper
• Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.

  2011influential citation
• Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

  2011cites this paper
• Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum‐based regimens

  2011cites this paper
• Vinflunine in the treatment of advanced bladder cancer

  2011cites this paper
• Chemotherapy for Metastatic Bladder Cancer

  2011cites this paper
• High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

  2011cites this paper
• Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study

  2011cites this paper
• Bladder cancer: current management and opportunities for a personalized approach.

  2010cites this paper
• Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

  2010cites this paper
• Tumorerkrankungen und medikamentöse Therapie

  2010cites this paper
• Systemic Therapy of Advanced Urothelial Cancer

  2009cites this paper
• Second-line therapy in bladder cancer

  2009cites this paper
• Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.

  2009cites this paper
• Current optimal chemotherapy for advanced urothelial cancer

  2008cites this paper
• Vinflunine in the treatment of bladder cancer

  2008cites this paper
• Advanced bladder cancer: Status of first‐line chemotherapy and the search for active agents in the second‐line setting

  2008cites this paper
• Recommendations 2007 en Onco-Urologie

  2007cites this paper
• [Urothelial tumors].

  2007cites this paper
• Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.

  2007cites this paper
• Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.

  2007cites this paper
• Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study

  2007cites this paper
• Paclitaxel Carboplatin chemotherapy as a second‐line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases

  2007cites this paper
• Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

  2007cites this paper
• Systemic chemotherapy for urothelial cancer.

  2006cites this paper
• Cancer research training: the Southwest Oncology Group young investigator training program (YITP).

  2006cites this paper
• Bibliography. Current world literature. Bladder cancer.

  2006cites this paper
• Chemotherapie des Harnblasenkarzinoms

  2003cites this paper